Please ensure Javascript is enabled for purposes of website accessibility
Maxx Chatsko

Maxx Chatsko

XMFBlacknGoldX

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

254 binoculars

Renewable Energy Group and Phillips 66 Pulled the Plug on Partnership. What's Next?

A long-awaited and very important joint venture has been sidelined indefinitely. It could hurt investors in the long run.


028 green battery light

Here's Why Lithium Stocks Were Soaring Today

Investors are coming around to the idea that global demand for lithium-ion batteries is about to pick up.


302 is a buy

Is Sol-Gel Technologies a Buy?

The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments.


076 arrow dude getty

Here's Why Amyris Shares Rose as Much as 12.5% Today

Another year, another set of financing transactions that provide a lifeline to the struggling company.


600 businessman winning

Is Apellis Pharmaceuticals a Buy?

The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.

scientist dejected

Here's Why These Small-Cap Pharma Stocks Are Volatile Today

Two stocks fell, while one popped, as investors speculate over the potential financial impact from the Wuhan coronavirus outbreak. (Hint: it's unlikely to move the needle.)


600 scientist microscope

Codexis Is Chasing a Blockbuster Opportunity. Can It Compete With Gene Therapies?

The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.


557 doctor visit

Coronavirus Uncertainty Spreads, but Investors Should Remain Calm

If you wouldn't invest in flu vaccines, then you shouldn't view the ongoing coronavirus outbreak as a noteworthy investing opportunity.


paper airplanes rising

Here's Why Adaptive Biotechnologies Is Soaring Today

The genetic diagnostics company announced the pricing of a common stock offering that suggests there's solid demand for shares.


600 businessman winning

2 Top Biotech Stocks to Buy Right Now

These two companies are pushing the envelope of immunotherapies by developing unique cell types. Each has promising results for investors to consider.

600 scientist microscope

Here's Why Moderna Stock Rose as Much as 10.8% Today

The company is working on a vaccine to protect against the latest coronavirus spreading from China, but investors are getting a little ahead of themselves.


scientist dejected

Here's Why Arrowhead Pharmaceuticals Lost as Much as 14.2% Today

The biopharma stock received an analyst downgrade.


soybeans in field

These Gene-Editing Pioneers Are Making Bold Bets in Agriculture

Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.


chalkboard stock down pink

Here's Why Coeur Mining Stock Fell as Much as 17.5% Today

The precious-metals miner reported preliminary results for the fourth quarter of 2019.


027 green sprout soil

2 Stocks to Buy and Hold for Decades

These companies aren't household names, but they quietly enable customers across the pharmaceutical and biopharmaceutical sectors to bring innovative new products to market.

dude tossing stacks

2 Top Dividend Stocks to Buy in January

These two businesses generate comfortable levels of cash flow, return some of that to investors, and have healthy growth opportunities ahead.


multiple lines up

Here's Why Rigel Pharmaceuticals Is Erupting This Week

The pharmaceutical stock is surging after providing preliminary results for the fourth quarter of 2019.


079 solar panel city

2 Top Renewable Energy Stocks to Buy Right Now

These two renewable energy stocks offer investors a way to own a piece of the ongoing energy transition, which will accelerate in the 2020s.


076 arrow dude getty

Here's Why Clovis Oncology Rose as Much as 25.6% Today

Investors might be getting a little carried away with news from the FDA.


152 building blocks stairs

2 Top Growth Stocks to Buy in January

Two pharma stocks, one riding a wave of enthusiasm and one getting unfairly punished, look appealing from a long-term standpoint.